Compare ELA & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELA | AARD |
|---|---|---|
| Founded | 1965 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.6M | 297.2M |
| IPO Year | N/A | 2025 |
| Metric | ELA | AARD |
|---|---|---|
| Price | $12.55 | $14.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $11.50 | ★ $31.11 |
| AVG Volume (30 Days) | 98.0K | ★ 221.0K |
| Earning Date | 11-05-2025 | 02-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.79 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $208,843,961.00 | N/A |
| Revenue This Year | $19.13 | N/A |
| Revenue Next Year | $2.46 | N/A |
| P/E Ratio | $34.12 | ★ N/A |
| Revenue Growth | ★ 23.18 | N/A |
| 52 Week Low | $5.10 | $4.88 |
| 52 Week High | $15.09 | $19.58 |
| Indicator | ELA | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 52.23 | 59.57 |
| Support Level | $11.00 | $12.78 |
| Resistance Level | $13.64 | $15.00 |
| Average True Range (ATR) | 1.09 | 0.92 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 43.40 | 61.84 |
Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.